ReviewsGout Where Is the Weak Link?Pascual, Eliseo MD, PhD∗,†; Andres, Mariano MD, PhD∗,†,‡; Sivera, Francisca MD, PhD∗,§ Author Information From the ∗Department of Medicine, University Miguel Hernandez, Elche †Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL) ‡Department of Rheumatology; Hospital General Universitario de Alicante, Alicante §Department of Rheumatology; Hospital General Universitario de Elda, Elda, Spain. This study had no external funding source. E.P. declares no conflict of interest. M.A. has received speaking and advisory fees from Menarini, AstraZeneca, Grünenthal, and Horizon. F.S. has received speaking and advisory fees from Menarini, AstraZeneca, Grünenthal, and Horizon. All authors contributed to the drafting of the manuscript and approved the final version. Correspondence: Eliseo Pascual, MD, PhD, Universidad Miguel Hernandez. Carretera Nacional 332 s/n, 03550, San Juan de Alicante, Alicante, Spain. E-mail: [email protected]. JCR: Journal of Clinical Rheumatology: August 2020 - Volume 26 - Issue 5 - p 208-212 doi: 10.1097/RHU.0000000000001492 Buy Metrics Abstract In the field of rheumatic and musculoskeletal diseases, no other condition has evolved so significantly since the mid-1950s as gout. In this period, the cause of gout has been firmly established; the close relationship with other conditions clarified; a rapid, unequivocal diagnostic test established; and agents effective in dissolving monosodium urate crystals and controlling inflammation made widely available. All these insights have ultimately led to deem gout as curable, an end point formerly considered out of reach. Unfortunately, diagnosis and management of gout in clinical practice have not paralleled the scientific advances and remain far from established quality standards. This paradox is the topic of the present review article, intending to increase the widespread interest of clinicians in gout. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.